Drug News

Laekna, Inc. Releases 2023 ESG Report: A Testament to Sustainable Growth and Corporate Responsibility

Laekna, Inc. (2105.HK), a prominent player in the biotechnology and drug development landscape, unveiled its highly anticipated 2023 Environmental, Social, and Governance (ESG) report today, marking a significant milestone since its listing on the Hong Kong Stock Exchange (HKEX) in June 2023. The release of the report underscores Laekna’s unwavering commitment to sustainable growth, ethical governance, and corporate responsibility.

Laekna, which derives its name from the Mandarin word meaning “to cure, to heal,” has remained steadfast in its mission of healing and caring for patients since its inception. This mission forms the bedrock of the company’s ethos and serves as a guiding principle in its pursuit of excellence in ESG practices.

Upholding ESG Excellence

At the helm of Laekna’s ESG initiatives is Dr. Chris Lu, the Chairman and CEO, whose leadership has been instrumental in shaping the company’s approach to sustainability. Dr. Lu emphasized the importance of ESG principles, highlighting the company’s commitment to maintaining high standards despite its size.

“In ESG work, I’ve learned two key lessons: never tire of small acts of kindness and maintain high standards despite our size,” remarked Dr. Lu. “Despite our capabilities being limited, our collective compassion shines through. We uphold compliance, ethics, and ESG as essential pillars of our operations.”

Key Highlights of the 2023 ESG Report

Laekna’s 2023 ESG report provides a comprehensive overview of the company’s achievements and commitments across various dimensions:

Corporate Governance: The report highlights Laekna’s strict adherence to laws and regulations, including those stipulated by the HKEX. The company has implemented a robust framework of policies and procedures, covering areas such as Conflict of Interest Management and Insider Information Governance. Notably, Laekna achieved a 100% compliance training coverage rate among its workforce, underscoring its commitment to upholding governance standards.

R&D Innovation: Laekna’s commitment to innovation is evident in its pursuit of cutting-edge research and development activities. The company initiated six clinical trials and internally discovered 14 drug candidates, with seven advancing into the Preclinical Candidate (PCC) stage. Furthermore, Laekna has taken significant steps to safeguard intellectual property rights through patent applications and legal enforcement measures.

Community Investment: Laekna actively engages in various social welfare activities and donations, making a tangible impact on communities. Initiatives such as donating books and establishing science innovation classrooms demonstrate the company’s commitment to education and community development. Laekna’s employees also dedicated significant volunteer hours to public welfare programs, furthering the company’s ethos of corporate citizenship.

Diversity, Equity, and Inclusion: Laekna places a strong emphasis on fostering a diverse and inclusive workplace environment. The company has made notable strides in gender diversity, with female employees comprising 64% of the workforce and women holding approximately 53% of director-level and above positions.

Talent Development: Laekna prioritizes the professional development of its employees, offering a range of training and career advancement opportunities. The company’s commitment to recognizing and rewarding employee contributions is evident in its internal knowledge-sharing events and training initiatives.

Partnering with Stakeholders: Laekna emphasizes the importance of cultivating resilient and compassionate partnerships with stakeholders, including suppliers and charitable organizations. By prioritizing responsible and low-risk supply chain practices, the company contributes to broader social and environmental objectives.

Green Operation: Environmental sustainability remains a key focus area for Laekna, with initiatives aimed at minimizing pollutant emissions and reducing environmental footprint. The company’s transition from single-use consumables to reusable alternatives contributed to a 20% reduction in GHG emissions during the reporting period.

A Testament to Sustainable Growth

In conclusion, Laekna’s 2023 ESG report serves as a testament to the company’s commitment to sustainable growth and corporate responsibility. Through its comprehensive ESG framework and steadfast adherence to ethical principles, Laekna continues to set the standard for excellence in the biotechnology industry.

As the company looks to the future, it remains guided by its mission to heal, innovate, and make a positive impact on society. With Dr. Chris Lu at the helm, Laekna is poised to continue its journey of growth and transformation, driving positive change in the healthcare landscape and beyond.


Joan David-Leonhard

Joan David Leonhard is a recent Pharm.D graduate with a strong passion for the pharmaceutical industry and a particular interest in pharmaceutical media and communication. Her brief internship experience includes roles in pharmacy where she built strong patient-pharmacist relationships and a pharmaceutical media internship where she actively contributed to drug information articles, blog posts, social media engagement, and various media projects.
Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker